Fortress Biotech, Inc.

  • Home
  • About
    • Overview
    • Business Development
    • Management Team
    • Board of Directors
    • FAQ
  • Programs
    • Pipeline
    • Marketed Products
    • Publications
  • News & Media
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Resources
  • Contact
  • Careers
  • Accessibility Statement

Press Releases

Investors

Investors

  • Overview
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
    • Annual Meeting Materials
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Resources
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Mustang Bio Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights

Aug 14, 2017

Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights

Aug 11, 2017

Fortress Biotech Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights

Aug 09, 2017

Fortress Biotech Announces Filing of Provisional Patent Application for Caelum Biosciences’ CAEL-101

Jul 17, 2017

Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics

Jul 03, 2017

Avenue Therapeutics Completes Initial Public Offering

Jun 30, 2017

Avenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock

Jun 26, 2017

Checkpoint Therapeutics Commences Trading on the NASDAQ Capital Market

Jun 26, 2017

Fortress Biotech to Present at the 2017 BIO International Convention

Jun 15, 2017

Fortress Biotech Announces that its Subsidiary, Mustang Bio, Enters into License Agreements with City of Hope for Novel CAR T Immunotherapies

Jun 05, 2017
RSS
  • Prev
    • 1...
    • 34
    • 35
    • 36
    • 37
    • 38
    • 39
    • 40
    • 41
    • 42
    • 43
    Next
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed

    Fortress Biotech programs include product candidates in development at Fortress, its majority-owned and majority-controlled partner companies and entities in which it holds minority ownership positions.

    © 2022 Fortress Biotech, Inc. All Rights Reserved.
    Facebook Twitter Linkedin
    Accessibility Statement Privacy Policy Disclaimer Sitemap